Cytokinetics (NASDAQ:CYTK) Given Market Outperform Rating at JMP Securities
JMP Securities restated their market outperform rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a research note released on Friday morning,Benzinga reports. JMP Securities currently has a $78.00 price objective on the biopharmaceutical company’s stock. A number of other research firms have also recently weighed in on CYTK. Royal Bank of Canada increased […]
JMP Securities restated their market outperform rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a research note released on Friday morning,Benzinga reports. JMP Securities currently has a $78.00 price objective on the biopharmaceutical company’s stock. A number of other research firms have also recently weighed in on CYTK. Royal Bank of Canada increased […]
